CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Vitrolife Publishes Q3 2026 Interim Report and Presentation

By Public Technologies
  • Vitrolife’s third-quarter 2026 net sales rose 6% to SEK 884 million.
  • EBITDA reached SEK 279 million, with the margin widening to 31.6% from 30.3%.
  • Net income increased to SEK 124 million from SEK 102 million; earnings per share reached SEK 0.94.
  • Operating cash flow fell to SEK 224 million from SEK 255 million, mainly reflecting weaker working capital contributions.
  • Restructuring delivered SEK 20 million in quarterly savings, with gross headcount reduced by 8%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vitrolife AB published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk